XFOR
X4 Pharmaceuticals Inc
NASDAQ: XFOR · HEALTHCARE · BIOTECHNOLOGY
$4.50
-4.49% today
Updated 2026-06-05
Market cap
$377.28M
P/E ratio
—
P/S ratio
41.85x
EPS (TTM)
$-2.07
Dividend yield
—
52W range
$1 – $5
Volume
0.4M
X4 Pharmaceuticals Inc (XFOR) Insider transactions
Net insider activity
Net buying (25,258,885 shares)
Buy transactions
66
Sell transactions
34
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-12 | KIRSKE, DAVID | Chief Financial Officer | Sale | 16,961 | $4.29 | $72820.36 |
| 2026-01-01 | WYZGA, MICHAEL S | Director | Buy | 110,000 | — | — |
| 2026-01-01 | STEWART, MURRAY | Director | Buy | 110,000 | — | — |
| 2026-01-01 | DE, CRAECKER FRANCOISE | Director | Buy | 110,000 | — | — |
| 2026-01-01 | BRIDGER, GARY | Director | Buy | 110,000 | — | — |
| 2025-10-29 | VOLPONE, JOHN | President | Buy | 2,329,154 | — | — |
| 2025-10-29 | KIRSKE, DAVID | Chief Financial Officer | Buy | 1,552,769 | — | — |
| 2025-10-29 | CRAIG, ADAM R | Director, Executive Chairman | Buy | 2,329,154 | — | — |
| 2025-10-23 | CRAIG, ADAM R | Director, Executive Chairman | Buy | 86,206 | $2.90 | $249997.40 |
| 2025-08-14 | VOLPONE, JOHN | President | Buy | 529,201 | — | — |
| 2025-08-14 | VOLPONE, JOHN | President | Buy | 289,881 | — | — |
| 2025-08-14 | KIRSKE, DAVID | Chief Financial Officer | Buy | 352,800 | — | — |
| 2025-08-14 | KIRSKE, DAVID | Chief Financial Officer | Buy | 193,254 | — | — |
| 2025-08-14 | CRAIG, ADAM R | Director, Executive Chairman | Buy | 529,201 | — | — |
| 2025-08-14 | CRAIG, ADAM R | Director, Executive Chairman | Buy | 289,881 | — | — |
| 2025-08-12 | VOLPONE, JOHN | President | Buy | 1,609,873 | — | — |
| 2025-08-12 | KIRSKE, DAVID | Chief Financial Officer | Buy | 1,073,249 | — | — |
| 2025-08-12 | CRAIG, ADAM R | Director, Executive Chairman | Buy | 1,609,873 | — | — |
| 2025-06-09 | WYZGA, MICHAEL S | Director | Buy | 1,500 | — | — |
| 2025-06-09 | WOODS, KEITH | Director | Buy | 1,500 | — | — |
| 2025-06-09 | STEWART, MURRAY | Director | Buy | 1,500 | — | — |
| 2025-06-09 | MCGIRR, DAVID W J | Director | Buy | 1,500 | — | — |
| 2025-06-09 | DE, CRAECKER FRANCOISE | Director | Buy | 1,500 | — | — |
| 2025-06-09 | BRIDGER, GARY | Director | Buy | 1,500 | — | — |
| 2025-05-20 | THOREN, NATASHA FAY | Chief Legal Officer | Buy | 3,333 | — | — |
| 2025-05-16 | BALDRY, MARK | Chief Commercial Officer | Buy | 1,032 | $2.48 | $2561.42 |
| 2025-02-12 | RAGAN, PAULA | Director, President and CEO | Buy | 2,250,000 | — | — |
| 2025-02-12 | MOSTAFA, ADAM S. | Chief Financial Officer | Buy | 850,000 | — | — |
| 2025-02-12 | DIBIASE, MARY | Chief Operating Officer | Buy | 650,000 | — | — |
| 2025-02-12 | BALDRY, MARK | Chief Commercial Officer | Buy | 600,000 | — | — |
| 2025-02-12 | ARBET-ENGELS, CHRISTOPHE | Chief Medical Officer | Buy | 850,000 | — | — |
| 2025-01-24 | RAGAN, PAULA | Director, President and CEO | Sale | 76,473 | $0.45 | $34718.74 |
| 2025-01-24 | MOSTAFA, ADAM S. | Chief Financial Officer | Sale | 74,773 | $0.45 | $33946.94 |
| 2025-01-24 | DIBIASE, MARY | Chief Operating Officer | Sale | 22,258 | $0.45 | $10094.00 |
| 2025-01-24 | BALDRY, MARK | Chief Commercial Officer | Sale | 29,159 | $0.45 | $13241.10 |
| 2025-01-24 | ARBET-ENGELS, CHRISTOPHE | Chief Medical Officer | Sale | 11,624 | $0.45 | $5284.27 |
| 2025-01-23 | RAGAN, PAULA | Director, President and CEO | Buy | 169,940 | — | — |
| 2025-01-23 | MOSTAFA, ADAM S. | Chief Financial Officer | Buy | 74,773 | — | — |
| 2025-01-23 | DIBIASE, MARY | Chief Operating Officer | Buy | 61,178 | — | — |
| 2025-01-23 | BALDRY, MARK | Chief Commercial Officer | Buy | 74,773 | — | — |
| 2025-01-23 | ARBET-ENGELS, CHRISTOPHE | Chief Medical Officer | Buy | 25,831 | — | — |
| 2024-11-15 | RAGAN, PAULA | Director, President and CEO | Sale | 31,897 | $0.39 | $12583.37 |
| 2024-11-15 | BALDRY, MARK | Chief Commercial Officer | Buy | 13,404 | $0.34 | $4597.57 |
| 2024-10-15 | RAGAN, PAULA | Director, President and CEO | Sale | 31,897 | $0.56 | $17926.11 |
| 2024-10-07 | TAVERAS, ARTHUR | Chief Scientific Officer | Sale | 76,920 | $0.56 | $43305.96 |
| 2024-10-07 | RAGAN, PAULA | Director, President and CEO | Sale | 239,436 | $0.55 | $131522.19 |
| 2024-10-07 | MOSTAFA, ADAM S. | Chief Financial Officer | Sale | 230,645 | $0.55 | $126900.88 |
| 2024-10-07 | DIBIASE, MARY | Chief Operating Officer | Sale | 67,695 | $0.57 | $38328.91 |
| 2024-10-07 | BALDRY, MARK | Chief Commercial Officer | Sale | 11,127 | $0.58 | $6505.96 |
| 2024-10-04 | TAVERAS, ARTHUR | Chief Scientific Officer | Buy | 230,645 | — | — |
| 2024-10-04 | RAGAN, PAULA | Director, President and CEO | Buy | 532,081 | — | — |
| 2024-10-04 | MOSTAFA, ADAM S. | Chief Financial Officer | Buy | 230,645 | — | — |
| 2024-10-04 | DIBIASE, MARY | Chief Operating Officer | Buy | 230,645 | — | — |
| 2024-10-04 | BALDRY, MARK | Chief Commercial Officer | Buy | 34,946 | — | — |
| 2024-09-09 | DIBIASE, MARY | Chief Operating Officer | Sale | 2,642 | $0.66 | $1737.64 |
| 2024-06-10 | WYZGA, MICHAEL S | Director | Buy | 45,000 | — | — |
| 2024-06-10 | WOODS, KEITH | Director | Buy | 45,000 | — | — |
| 2024-06-10 | STEWART, MURRAY | Director | Buy | 45,000 | — | — |
| 2024-06-10 | MCGIRR, DAVID W J | Director | Buy | 45,000 | — | — |
| 2024-06-10 | LAWTON, ALISON FRANCES | Director | Buy | 45,000 | — | — |
| 2024-06-10 | DE, CRAECKER FRANCOISE | Director | Buy | 45,000 | — | — |
| 2024-06-10 | BRIDGER, GARY | Director | Buy | 45,000 | — | — |
| 2024-06-10 | ALISKI, WILLIAM | Director | Buy | 45,000 | — | — |
| 2024-05-17 | BALDRY, MARK | Chief Commercial Officer | Buy | 21,646 | $0.68 | $14654.34 |
| 2024-03-11 | TAVERAS, ARTHUR | Chief Scientific Officer | Sale | 14,235 | $0.88 | $12552.42 |
| 2024-03-11 | RAGAN, PAULA | Director, President and CEO | Sale | 49,678 | $0.88 | $43855.74 |
| 2024-03-11 | MOSTAFA, ADAM S. | Chief Financial Officer | Sale | 52,500 | $0.88 | $46347.00 |
| 2024-03-11 | DIBIASE, MARY | Chief Operating Officer | Sale | 15,409 | $0.88 | $13590.74 |
| 2024-02-13 | TAVERAS, ARTHUR | Chief Scientific Officer | Buy | 428,248 | — | — |
| 2024-02-13 | RAGAN, PAULA | Director, President and CEO | Buy | 1,189,578 | — | — |
| 2024-02-13 | MOSTAFA, ADAM S. | Chief Financial Officer | Buy | 523,414 | — | — |
| 2024-02-13 | DIBIASE, MARY | Chief Operating Officer | Buy | 428,248 | — | — |
| 2024-02-13 | BALDRY, MARK | Chief Commercial Officer | Buy | 523,414 | — | — |
| 2024-02-13 | ARBET-ENGELS, CHRISTOPHE | Chief Medical Officer | Buy | 475,831 | — | — |
| 2024-02-13 | ARBET-ENGELS, CHRISTOPHE | Chief Medical Officer | Buy | 180,816 | — | — |
| 2024-02-12 | TAVERAS, ARTHUR | Chief Scientific Officer | Sale | 787 | $1.01 | $792.67 |
| 2024-02-12 | RAGAN, PAULA | Director, President and CEO | Sale | 21,695 | $1.01 | $21892.42 |
| 2024-02-12 | MOSTAFA, ADAM S. | Chief Financial Officer | Sale | 27,721 | $1.01 | $27973.26 |
| 2024-02-12 | DIBIASE, MARY | Chief Operating Officer | Sale | 3,683 | $1.01 | $3708.78 |
| 2023-11-03 | RAGAN, PAULA | Director, President and CEO | Sale | 39,906 | $0.90 | $35915.40 |
| 2023-11-01 | TAVERAS, ARTHUR | Chief Scientific Officer | Sale | 67,695 | $0.73 | $49417.35 |
| 2023-11-01 | RAGAN, PAULA | Director, President and CEO | Sale | 199,531 | $0.73 | $145657.63 |
| 2023-11-01 | MOSTAFA, ADAM S. | Chief Financial Officer | Sale | 230,645 | $0.73 | $168370.85 |
| 2023-11-01 | DIBIASE, MARY | Chief Operating Officer | Sale | 67,695 | $0.73 | $49417.35 |
| 2023-11-01 | BALDRY, MARK | Chief Commercial Officer | Sale | 10,257 | $0.73 | $7487.61 |
| 2023-10-31 | TAVERAS, ARTHUR | Chief Scientific Officer | Buy | 230,645 | — | — |
| 2023-10-31 | RAGAN, PAULA | Director, President and CEO | Buy | 532,081 | — | — |
| 2023-10-31 | MOSTAFA, ADAM S. | Chief Financial Officer | Buy | 230,645 | — | — |
| 2023-10-31 | DIBIASE, MARY | Chief Operating Officer | Buy | 230,645 | — | — |
| 2023-10-31 | BALDRY, MARK | Chief Commercial Officer | Buy | 34,947 | — | — |
| 2023-10-16 | WOODS, KEITH | Director | Buy | 90,000 | — | — |
| 2023-09-08 | DIBIASE, MARY | Chief Operating Officer | Sale | 2,642 | $1.25 | $3299.86 |
| 2023-08-31 | ARBET-ENGELS, CHRISTOPHE | Chief Medical Officer | Buy | 1,250,000 | $1.28 | $1.60M |
| 2023-08-18 | WYZGA, MICHAEL S | Director | Buy | 25,000 | $1.20 | $29875.00 |
| 2023-08-10 | STEWART, MURRAY | Director, Interim Chief Medical Officer | Sale | 130,056 | $1.06 | $137859.36 |
| 2023-08-09 | STEWART, MURRAY | Director, Interim Chief Medical Officer | Buy | 269,893 | — | — |
| 2023-06-30 | MOSTAFA, ADAM S. | Chief Financial Officer | Sale | 2,641 | $1.89 | $4991.49 |
| 2023-06-30 | DIBIASE, MARY | Chief Operating Officer | Sale | 464 | $1.89 | $876.96 |
| 2023-06-23 | RAGAN, PAULA | Director, President and CEO | Sale | 6,724 | $1.92 | $12910.08 |
| 2023-06-23 | MOSTAFA, ADAM S. | Chief Financial Officer | Sale | 5,417 | $1.93 | $10454.81 |
Frequently asked questions
Are XFOR insiders buying or selling?
Over the transactions on record, XFOR insiders have been net buyers, with about $1.35M in stock sold across 34 sales, against 6 open-market purchases.
Does insider selling at XFOR mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which XFOR insiders are selling the most?
Recent selling is concentrated in a few names. RAGAN, PAULA accounts for the largest share on record, with about $456981.69 sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.